Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain-Reference-Cited by-同舟云学术

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

Published:2011-12 Issue:3 Volume:74 Page:529-534
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Banz Kurt,Bischoff Helge,Brunner Matthias,Chouaid Christos,de Castro Carpeño Javier,de Marinis Filippo,Grossi Francesco,Vergnenègre Alain,Walzer Stefan

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. World Health Organization, Fact sheet No. 297, February 2009. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/index.html [accessed 23.06.10].

2. GLOBOCAN 2008, International Agency for Research of Cancer, Lyon, France. Available from: http://globocan.iarc.fr/ [accessed 23.06.10].

3. Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database;Navada;J Clin Oncol,2006

4. Small cell lung cancer;Sher;Mayo Clin Proc,2008

5. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial;Brodowicz;Lung Cancer,2006

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy;Clinical Drug Investigation;2024-08

2. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer;Future Oncology;2024-04

3. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy;PharmacoEconomics;2024-01-09

4. Benefits of the Involvement of Dentists in Managing Oral Complications Among Patients With Oral Cavity and Oropharyngeal Cancer: An Analysis of Claims Data;JCO Oncology Practice;2021-11

5. Direct costs associated with the management of mucositis: A systematic review;Oral Oncology;2021-07